Atara Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
(In thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Additional · Other · Total | ||||||
| Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity (Deficit) | |
| Balance as of January, 1 2024 | 4,258 | $— | $1,870,123 | $(204) | $(1,969,150) | $(99,231) |
| Issuance of common stock and pre-funded warrants to purchase common stock through a registered direct offering, net of offering costs of $397 | 759 | 1 | 50,602 | — | — | 50,603 |
| Issuance of common stock through ATM facilities, net of commissions and offering costs of $168 | 493 | — | 9,312 | — | — | 9,312 |
| Exercise of pre-funded warrants | 9 | — | — | — | — | - |
| RSU settlements, net of shares withheld | 314 | — | (7) | — | — | (7) |
| Issuance of common stock pursuant to employee stock awards | 26 | — | 230 | — | — | 230 |
| Stock-based compensation expense | — | — | 27,001 | — | — | 27,001 |
| Net loss | — | — | — | — | (85,403) | (85,403) |
| Unrealized gain (loss) on available-for-sale securities | — | — | — | 212 | — | 212 |
| Balance as of December 31, 2024 | 5,859 | 1 | 1,957,261 | 8 | (2,054,553) | (97,283) |
| Issuance of common stock and pre-funded warrants to purchase common stock through a registered direct offering, net of offering costs of $522 | 834 | — | 14,843 | — | — | 14,843 |
| Issuance of common stock through ATM facilities, net of commissions and offering costs of $48 | 125 | — | 1,471 | — | — | 1,471 |
| Exercise of pre-funded warrants | 49 | — | — | — | — | - |
| RSU settlements, net of shares withheld | 453 | — | (1) | — | — | (1) |
| Issuance of common stock pursuant to employee stock awards | 4 | — | 35 | — | — | 35 |
| Stock-based compensation expense | — | — | 9,752 | — | — | 9,752 |
| Net income | — | — | — | — | 32,688 | 32,688 |
| Unrealized gain (loss) on available-for-sale securities | — | — | — | (7) | — | (7) |
| Balance as of December 31, 2025 | 7,324 | $1 | $1,983,361 | $1 | $(2,021,865) | $(38,502) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.